Allspring Global Investments
HUMA icon

Allspring Global Investments’s Humacyte HUMA Stock Holding History

Allspring Global Investments’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,885
Closed -$11.4K – 2453
2023
Q3 		$11.4K Sell
3,885
-22,780
-85% -$75.4K ﹤0.01% 2597
2023
Q2 		$76.3K Buy
26,665
+10,186
+62% +$36.7K ﹤0.01% 2153
2023
Q1 		$50.9K Buy
+16,479
New +$46.9K ﹤0.01% 2280

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Allspring Global Investments's HUMA Position: Q4 2023 in Review

Allspring Global Investments sold out of Humacyte (HUMA) in Q4 2023, closing a stake of 3,885 shares — an estimated $11.4K sold.

Allspring Global Investments first reported a position in HUMA in Q1 2023 and held it in 3 quarters. The position peaked at $76.3K in Q2 2023. 88 funds tracked by Wall St. Rank hold HUMA as of Q4 2023.

  • Allspring Global Investments reported no remaining Humacyte position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 3,885 Humacyte shares in Q4 2023, an estimated $11.4K.
  • Allspring Global Investments first reported a position in Humacyte in Q1 2023 and held it in 3 quarters.
  • Allspring Global Investments's Humacyte position peaked at $76.3K in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Humacyte as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.